We are monitoring the impact of COVID-19 on MEA Biologics Market Get in touch with us for detailed analysis Know More
Pulished Date June, 2021
ID: 11721
Share on
Share on

Middle East & Africa Biologics Market Research Report – Segmented By Source, Product, Biologics Manufacturing Type, Disease Category and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends, Growth & Forecast (2021 to 2026)

Pulished: June, 2021
ID: 11721
Pages: 90

MEA Biologics Market Size (2021 to 2026)

The Middle East & Africa biologics market size is expected to showcase a healthy growth rate during the forecast period.

MARKET DRIVERS:

There is an increase in High Throughput Screening (HTS) technology in the Middle East and Africa for various drug development processes. The technology is used to identify threads to discover an inhibitor of Middle East Respiratory Syndrome (MERS). This factor is attributed to fuel the growth rate of the biologics market in the MEA region. The increasing prevalence of diseases such as AIDS, Alzheimer's disease, and other drug-resistant infectious diseases has also led to the discovery new bioactive compounds that are likely to boost the market's growth rate.

Supply management for clinical trials is necessary to avoid overproduction, oversupply, and expiration of stocks. With the rising costs of drug discovery, supplies for clinical trials are gaining in importance. Hence a subsequent increase in the market for biologics.

MARKET RESTRAINTS:

Biologic drugs are very complex and must be controlled and maintained throughout the development and production process. This regulated environment and these quality control procedures involve significant capital investment in the initial phase of the process. In addition, biologics products are more sensitive to light and hot conditions and require an extremely promising environment that is not uniformly available globally.

In most emerging markets today, biologics products are scarce. Strict regulatory policies and high capital investments, coupled with limited patient access to biologics, mainly in developing countries, due to increased control and the cost of access to biologics, are likely to 'hamper the growth of the biologics market in the Middle East and Africa in the coming years.

Impact of COVID-19 on the MEA biologics market:

Since the increase in COVID-19 cases, the pharmaceutical industry has decreased its production capacity, leading to drug shortages. In addition, the diversion of resources from drug development to treatment for coronaviruses is likely to hamper the overall productivity of drug development for a short period of time.

Several pharmaceutical companies have decided to postpone ongoing clinical R&D due to disrupted supply chains and the threat of the virus. The Middle East is struggling to control the crisis due to the limited supply of health care due to the sanctions imposed by the United States on the country.

Such restrictions are likely to have a negative impact on research and development activities, directly limiting the growth of the biologics products market in the Middle East and Africa.

This research report on the MEA Biologics Market has been segmented & sub-segmented into the following categories:

By Source:  

  • Microbial
  • Mammalian
  • Others

By Product:

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi, & Molecular Therapy
  • Others

By Biologics Manufacturing:

  • Outsourced
  • In-house

By Disease Category:

  • Oncology
  • Infectious Diseases
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the South African biologics market is estimated to be the most lucrative regional market in the MEA and is expected to register a promising growth rate during the forecast period. South Africa has started to focus on developing new drugs for progressive diseases. Due to the increase in acute and chronic diseases, the demand for small molecule therapies is increasing in the country. The Biosciences Unit of the Council for Scientific and Industrial Research (CSIR) is carrying out a large collaborative malaria research project with the help of biologics technology. Various public-private foundations fund the project, and more than 50 scientists contribute to the research project at various universities and research institutes in South Africa.

The UAE biologics market is another lucrative regional market and is predicted to showcase a healthy CAGR from 2021 to 2026. The country is dedicated to putting in place the necessary initiatives and infrastructure that could help develop the pharmaceutical value chain, which includes HTS, medical chemistry, and preclinical testing. This would increase drug biologics procedures, increase partnerships between companies and government organizations in the country to implement the process, and thus create wide opportunities for growth in the biologics market. These factors propel the demand of the market.

KEY MARKET PLAYERS:

A few prominent companies operating in the MEA biologics market profiled in this report are Johnson & Johnson (J&J), F Hoffmann-La Roche, Bristol-Myers Squibb, GlaxoSmithKline, AbbVie, Amgen, Sanofi, Eli Lilly and Company, Merck & Co., and Pfizer Inc.

  1. Introduction
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. Research Methodology
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Overview
    1. Executive Summary
    2. Key Inferences
    3. New Developments
  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. Market Segmentation
    1. By Source
      1. Microbial
      2. Mammalian
      3. Others
    2. By Product
      1. Monoclonal Antibodies
      2. Vaccines
      3. Recombinant Proteins
      4. Antisense, RNAi, & Molecular Therapy
      5. Others
    3. By Biologics Manufacturing
      1. Outsourced
      2. In-house
    4. By Disease Category
      1. Oncology
      2. Infectious Diseases
      3. Immunological Disorders
      4. Cardiovascular Disorders
      5. Hematological Disorders
      6. Others
  6. Geographical Analysis
    1. Introduction    
      1. Regional Trends   
      2. Impact Analysis    
      3. Y-o-Y Growth Analysis        
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      4. Market Attractiveness Analysis      
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      5.      Market Share Analysis   
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
    2. Middle East and Africa
      1. Introduction
      2. Middle East
      3. Africa
  7. Strategic Analysis
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. Market Leaders' Analysis
    1. Johnson & Johnson (J&J)
      1. Overview
      2. Product Analysis
      3. Strategic Evaluation and Operations
      4. Financial analysis
      5. Legal issues
      6. Recent Developments
      7. SWOT analysis
      8. Analyst View
    2. F Hoffmann-La Roche
    3. Bristol-Myers Squibb
    4. GlaxoSmithKline
    5. AbbVie
    6. Amgen
    7. Sanofi
    8. Eli Lilly and Company
    9. Merck & Co.
    10. Pfizer
  9. Competitive Landscape
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. Market Outlook and Investment Opportunities
  11. Appendix
    1. List of Tables
    2. List of Figures  
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. Middle East and Africa Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  2. Middle East and Africa Microbial Market, By Region, From 2021 to 2026 (USD Billion)
  3. Middle East and Africa Mammalian Market, By Region, From 2021 to 2026 (USD Billion)
  4. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  5. Middle East and Africa Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  6. Middle East and Africa Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  7. Middle East and Africa Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  8. Middle East and Africa Recombinant Proteins Market, By Region, From 2021 to 2026 (USD Billion)
  9. Middle East and Africa Antisense, RNAi, & Molecular Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  10. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  11. Middle East and Africa Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  12. Middle East and Africa Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  13. Middle East and Africa In-house Market, By Region, From 2021 to 2026 (USD Billion)
  14. Middle East and Africa Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  15. Middle East and Africa Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  16. Middle East and Africa Infectious Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  17. Middle East and Africa Immunological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  18. Middle East and Africa Cardiovascular Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  19. Middle East and Africa Hematological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  20. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  21. Middle East Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  22. Middle East Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  23. Middle East Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  24. Middle East Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  25. Africa Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  26. Africa Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  27. Africa Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  28. Africa Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample